Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics
- Current Hematologic Malignancy Reports
Authors: Srinath Sundararajan, Abhijeet Kumar, Neha Korde, Amit Agarwal
Publisher: Springer US
Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10–60 %.
Absence of myeloma-defining events (MDE) or amyloidosis.
Factors Affecting Progression to Multiple Myeloma
Treatment Paradigms of Smoldering Myeloma
Bisphosphonates and Combinations
Clinical trial no.
Phase II study to evaluate fenofibrate therapy in patients with smoldering or symptomatic multiple myeloma
A study to evaluate three dose schedules of daratumumab in participants with smoldering multiple myeloma
KRd induction, high dose melphalan with transplant, KRd consolidation and Rd maintenance.
Carfilzomib in treatment patients under 65 years with high-risk smoldering multiple myeloma
Lenalidomide or observation in treating patients with asymptomatic high-risk smoldering multiple myeloma
Jan 2026 (Final data collection for primary outcome).
Lenalidomide, dexamethasone, and anakinra.
Lenalidomide and dexamethasone with or without anakinra in treating patients with early stage multiple myeloma
Trial of combination of elotuzumab and lenalidomide +/− dexamethasone in high-risk smoldering multiple myeloma